Loading...
XSHE002581
Market cap910mUSD
Jan 13, Last price  
10.12CNY
1D
-0.59%
1Q
1.91%
Jan 2017
-58.30%
IPO
24.12%
Name

Shandong Sinobioway Biomedicine Co Ltd

Chart & Performance

D1W1MN
XSHE:002581 chart
P/E
—
P/S
15.53
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-8.35%
Revenues
430m
+20.36%
150,029,741177,251,964213,798,562247,173,208246,369,291285,343,999317,253,572319,139,852858,285,7221,264,879,4361,162,416,642664,593,783567,637,225276,830,417402,713,045357,080,537429,790,105
Net income
-332m
32,632,81637,042,78058,823,81570,255,75566,976,25086,270,93888,037,32681,478,735250,253,848417,695,144388,411,585063,383,5060271,001,6710-332,458,291
CFO
-37m
25,067,69546,888,20754,056,99585,712,12374,426,51563,035,34383,132,88380,108,148137,728,784169,315,097271,106,65574,456,07548,414,58118,510,19900-36,506,208
Dividend
Jun 21, 20160.05 CNY/sh
Earnings
May 22, 2025

Profile

Shandong Sinobioway Biomedicine Co., Ltd. manufactures and supplies trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, phosphorous acid, ethyl formate, nerve growth factor, and alfaron in China. The company also provides NOBEX, a murine nerve growth factor for injection; Anferon, a human recombinant interferon alpha 2b injection; and Jaferon, a human recombinant interferon alpha 2b spray. In addition, it offers Healive, an inactivated hepatitis A vaccine; Bilive, a combined hepatitis A and B Vaccine; Panflu, a pandemic influenza vaccine; Anflu, a preservative-free influenza virus vaccine; Panflu.1, a Type A H1N1 influenza vaccine; etc. Further, the company exports its products to approximately 20 counties and regions in Europe and the United States. Shandong Sinobioway Biomedicine Co., Ltd. was founded in 2000 and is headquartered in Zibo, China.
URL
http://www.sinobiowaymed.com.cn/
IPO date
May 20, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
429,790
20.36%
357,081
-11.33%
Cost of revenue
558,568
478,798
Unusual Expense (Income)
NOPBT
(128,778)
(121,718)
NOPBT Margin
Operating Taxes
8,885
13,593
Tax Rate
NOPAT
(137,664)
(135,310)
Net income
(332,458)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
13,838
163,876
Long-term debt
1,420
2,946
Deferred revenue
6,713
Other long-term liabilities
21,588
9,674
Net debt
(1,491,167)
(1,507,583)
Cash flow
Cash from operating activities
(36,506)
CAPEX
(4,319)
Cash from investing activities
256,649
Cash from financing activities
(211,141)
47,893
FCF
114,494
28,305
Balance
Cash
151,912
183,803
Long term investments
1,354,512
1,490,602
Excess cash
1,484,934
1,656,550
Stockholders' equity
1,147,272
1,611,402
Invested Capital
1,062,590
1,032,485
ROIC
ROCE
EV
Common stock shares outstanding
659,770
659,736
Price
14.60
-7.30%
15.75
-26.23%
Market cap
9,632,647
-7.30%
10,390,835
-26.23%
EV
8,246,740
8,978,188
EBITDA
(58,146)
(46,857)
EV/EBITDA
Interest
8,635
9,411
Interest/NOPBT